Disorders of left ventricular structure and function in chronic uremia: How often, why and what to do with it?

European Journal of Heart Failure

Volumn 1, Issue 4, 1999, Pages 327-336

  Dyadyk, O I ^a   Bagriy, A E ^b   Yarovaya, N F ^c  

^a Teatralniy Prospect   (Ukraine)

^b Member Europ Working Grp Heart F   (Ukraine)

^c Sportivnaja Street 12 ^*  (Ukraine)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ENDOTHELIN; PARATHYROID HORMONE; RECOMBINANT ERYTHROPOIETIN; VITAMIN D;

ANEMIA; CARDIOVASCULAR RISK; HEART ARRHYTHMIA; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE OVERLOAD; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE CONDUCTION DISTURBANCE; HEMODIALYSIS; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY TRANSPLANTATION; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SECONDARY HYPERPARATHYROIDISM; UREMIA;

CHRONIC DISEASE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; RISK FACTORS; UREMIA; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0033494831     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(99)00057-4     Document Type: Review

References (87)

1. Agodoa L.Y., Eggers P.W. Renal replacement therapy in the United States: data from the United States Renal Data System. Am J Kidney Dis. 25:1995;119-133.
2. Teraoka S., Toma H., Nihei H. et al. Current status of renal replacement therapy in Japan. Am J Kidney Dis. 25:1995;151-164.
3. Valderrabano F., Jones E.H.P., Mallick N.P. Report on management of renal failure in Europe, XXIV, 1993. Nephrol Dial Transplant. 10(Suppl 5):1995;1-25.
4. Brown J.H. Pre-transplant management: cardiovascular disease and bone disease. Nephrol Dial Transplant. 10(Suppl 1):1995;14-19.
5. Kasiske B.L., GuiJarro C., Massy Z.A., Wiederkehr M.R., Ma J. Cardiovascular disease after renal transplantation. J Am Soc Nephrol. 7:1996;158-165.
6. Raine A.E.G. Hypertension and ischaemic heart disease in renal transplant recipients. Nephrol Dial Transplant. 10(Suppl 1):1995;95-100.
7. Levey A.S., Eknoyan G. Cardiovascular disease in chronic renal disease. Nephrol Dial Transplant. 14:1999;828-833.
8. Ritz E., Lippert J., Keller Ch. Hypertension, cardiovascular complications and survival in diabetic patients on maintenance haemodialysis. Nephrol Dial Transplant. 10(Suppl 7):1995;43-46.
9. Foley R.N., Parfrey P.S., Harnett J.D. et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 47:1995;186-192.
10. Lindholm A., Albrechtsen D., Frodin L., Tufveson G., Persson N.H., Lundgren G. Ischaemic heart disease - major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation. 60:1995;451-457.
11. Rostand S.G., Rutsky E.A. Ischaemic heart disease in chronic renal failure: management considerations. Semin Dial. 2:1989;98-101.
12. Wheeler D.C. Ischaemic heart disease after renal transplantation: how to assess and minimize the risk. Nephrol Dial Transplant. 14:1999;1075-1077.
13. Foley R.N., Parfrey P.S., Harnett J.D., Kent G.M., Murray D.C., Barre P.K. The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol. 5:1995;2024-2031.
14. Amann K., Ritz E. Cardiac structure and function in renal disease. Curr Opin Nephrol Hypertens. 5:1996;102-106.
15. McGregor E., Jardine A.G., Murray L.S., Dargie H.J., Rodger R.S.C., Junor B.J.R., McMillan M.A., Briggs J.D. Pre-operative echocardiographic abnormalities and adverse outcome following renal transplantation. Nephrol Dial Transplant. 13:1998;1499-1505.
16. Parfrey P.S., Foley R.N., Harnett J.D., Kent G.M., Murray D.C., Barre P.E. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant. 11:1996;1277-1285.
17. London G.M., Fabiani F. Left ventricular dysfunction in end-stage renal disease: echocardiographic insights. Parfrey P.S., Harnett J.D. Cardiac dysfunction in chronic uremia. 1992;117-137 Kluwer Academic Publishers, Basel.
18. Silberberg J.S., Barre P.E., Prichard S.S., Sniderman A.D. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int. 36:1989;286-290.
19. Timio M., Lippi G., Venanzi C., Monarea C. Clinical aspects of left ventricular hypertrophy in uremia. Timio M., Wizemann V., Venanzi S. Cardionephrology. 1995;331-336 Editoriale Bios, Assisi, Italy.
20. Cannella G. Clues for understanding the pathogenesis of left ventricular hypertrophy in chronic uremia. Int J Artif Organs. 21:1998;378-383.
21. Parfrey P.S., Collingwood P., Foley R.N., Bahrle A. Left ventricular disorders detected by M-mode echocardiography in chronic uremia. Nephrol Dial Transplant. 11:1996;1328-1331.
22. Erturk S., Ertug A.E., Ates K., Duman N., Aslan S.M., Nergisoglu G., Diker E., Erol C., Karatan O., Erbay B. Relationship of ambulatory blood pressure monitoring data to echocardiographic findings in haemodialysis patients. Nephrol Dial Transplant. 11:1996;2050-2054.
23. Kunz K., Dimitrov Y., Muller S., Chantrel F., Hannedouche T. Uraemic cardiomyopathy. Nephrol Dial Transplant. 13(Suppl 4):1998;39-43.
24. Harnett J.D., Murphy B., Collingwood P., Purchase L., Kent G., Parfrey P.S. The reliability and validity of echocardiographic measurement of left ventricular mass index in hemodialysis patients. Nephron. 65:1993;212-214.
25. Greaves S.C., Gamble G.D., Collins J.F., Whalley G.A., Sharpe D.N. Determinants of left ventricular hypertrophy and systolic dysfunction in chronic renal failure. Am J Kidney Dis. 24:1994;768-776.
26. Tucker B., Fabbian F., Giles M., Thuraisingham R.C., Raine A.E.G., Baker L.R.I. Left ventricular hypertrophy and ambulatory blood pressure monitoring in chronic renal failure. Nephrol Dial Transplant. 12:1997;724-728.
27. Levy D., Garrison R.J., Davage D.D., Kannel W.B., Castelli W.P. Prognostic implications of echocardiographically determined left ventricular mass in The Framingham heart study. N Engl J Med. 322:1990;1561-1566.
28. Foley R.N., Parfrey P.S., Harnett J.D., Kent G.M., Murray D.C., Barre P.K. The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol. 5:1995;2024-2031.
29. Cannella G., Paoletti E. Myocardial hypertrophy in chronic renal failure: a multifactorial, reversible alteration. Contrib Nephrol. 119:1996;86-92.
30. London G.M. Heterogeneity of left ventricular hypertrophy - does it have clinical implications? Nephrol Dial Transplant. 13:1998;17-19.
31. Wizemann V., Timio M. Dialysis schedule-related fluid state and cardiovascular effects. Nephrol Dial Transplant. 13(Suppl 6):1998;91-93.
32. Ritz E., Koch M. Morbidity and mortality due to hypertension in patients with renal failure. Am J Kidney Dis. 21:1993;113-118.
33. Rodby R.A., Vonesh E.F., Korbet S.M.K. Blood pressures in hemodialysis and peritoneal dialysis using ambulatory blood pressure monitoring. Am J Kidney Dis. 23:1994;401-411.
34. Huting J., Kramer W., Schutterle G., Wizemann V. Analysis of left-ventricular changes associated with chronic haemodialysis. A non-invasive follow-up study. Nephron. 49:1988;284-290.
35. Rambausek M., Ritz E., Mall G., Katus H. Myocardial hypertrophy in rats with renal insufficiency. Kidney Int. 28:1985;775-787.
36. Baumgart P., Walger P., Gemen S., von Eiff M., Raidt H., Raahn K.H. Blood pressure elevation during the night in chronic renal failure, hemodialysis and after renal transplantation. Nephron. 57:1991;293-298.
37. Habib G.B., Mann D.L., Zoghbi W.A. Normalization of cardiac structure and function after regression of cardiac hypertrophy. Am Heart J. 128:1994;333-343.
38. Dahlöf B., Pennert K., Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a metaanalysis of 109 treatment studies. Am J Hypertens. 5:1992;95-110.
39. London G.M., Marchais S.J., Guerin A.P., Metivier F., Pannier B. Cardiac hypertrophy and arterial alterations in end-stage renal disease: Hemodynamic factors. Kidney Int. 43(Suppl 43):1993;S42-S49.
40. London G.M. Increased arterial stiffness in end-stage renal failure: why is it of interest to the clinical nephrologist? Nephrol Dial Transplant. 9:1994;1709-1712.
41. London G.M. The concept of ventricular/vascular coupling: functional and structural alterations of the heart and arterial vessels go in parallel. Nephrol Dial Transplant. 13:1998;250-253.
42. Ibels L.S., Alfrey A.L., Huffer W.E., Craswell P.W., Anderson J.T., Weil R. Arterial calcification and pathology in uremic patients undergoing dialysis. Am J Med. 66:1979;790-796.
43. Silberberg J.S., Rahal D.P., Patton D.R., Sniderman A.D. Role of anemia in the pathogenesis of left ventricular hypertrophy in end-stage renal disease. Am J Cardiol. 64:1989;222-224.
44. Sikole A., Polenakovic M., Spirovska V. et al. Analysis of heart morphology and function following erythropoietin treatment of anaemic dialysis patients. Artif Organs. 17:1993;977-984.
45. Wizemann V., Schäfer R., Kramer W. Follow-up of cardiac changes induced by anemia compensation in normotensive hemodialysis patients with left ventricular hypertrophy. Nephron. 64:1993;202-206.
46. Mann J.F.E. Hypertension and cardiovascular effects - long-term safety and potential long-term benefits of r-HuEPO. Nephrol Dial Transplant. 10(Suppl 2):1995;80-84.
47. Vanrenterghem Y., Vanwalleghem J. Benefits and concerns of treating pre-dialysis and renal transplant patients with recombinant human erythropoietin. Nephrol Dial Transplant. 13(Suppl 2):1998;13-15.
48. Macdougall I.C. How to get the best out of r-HuEPO. Nephrol Dial Transplant. 10(Suppl 2):1995;85-91.
49. Özkahya M., Ok E., Cirit M., Aydin S., Akcicek F., Basci A., Dorhout Mees E.J. Regression of left ventricular hypertrophy in haemodialysis patients by ultrafiltration and reduced salt intake without antihypertensive drugs. Nephrol Dial Transplant. 13:1998;1489-1493.
50. Hörl W.H., Riegel W. Cardiac depressant factors in renal disease. Circulation. 87(Suppl IV):1993;77-82.
51. Timio M. Cardiotoxicity of parathyroid hormone in chronic renal failure. Ital J Mineral Electrolyte Metab. 9:1995;19-24.
52. Amann K., Kronenberg G., Gehlen F., Wessels S., Orth S., Munter K., Ehmke H., Mall G., Ritz E. Cardiac remodelling in experimental renal failure - an immunohistochemical study. Nephrol Dial Transplant. 13:1998;1958-1966.
53. Drueke T., Fauchet N., Fleury J. et al. Effect of parathyroidectomy on left-ventricular function in hemodialysis patients. Lancet. 1:1980;112-114.
54. Zucchelli P., Santoro A., Zucchelli A. et al. Long-term effect of parathyroidectomy on cardiac and autonomic nervous system function in hemodialysis patients. Nephrol Dial Transplant. 3:1988;45-50.
55. Kakinuma Y., Kawamura T., Bills T., Yoshioka T., Ichikawa I., Fogo A. Blood pressure independent effect of angiotensin inhibition on vascular lesions of chronic renal failure. Kidney Int. 42:1992;46-55.
56. Suzuki H, Schaefer L, Schaefer RM et al. Long-term effects of converting enzyme inhibition on the heart in experimental uremia: prevention of cardiac hypertrophy and amelioration of myocardial cathepsin B activity. XIII-th International Congress of Nephrology, Spain, Madrid, 1995:535 (Abstract).
57. Cannella G. Left ventricular hypertrophy in the dialysed patient. What can be done about it? Nephrol Dial Transplant. 11:1996;418-420.
58. Levin A., Singer J., Thompson C.R., Ross H., Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis. 27:1996;347-354.
59. Amann K., Törnig J., Nichols C., Zeier M., Mall G., Ritz E. Effects of ACE-inhibitors, calcium channel blockers and their combination on renal and extrarenal structures in renal failure. Nephrol Dial Transplant. 10(Suppl 9):1995;33-38.
60. Cannella G., Paoletti E., Delfino R., Peloso G., Molinari S., Traverso G.B. Regression of left ventricular hypertrophy in hypertensive dialyzed uremic patients on long-term antihypertensive therapy. Kidney Int. 44:1993;881-886.
61. Cannella G., Paoletti E., Delfino R., Peloso G.C., Rolla D., Molinari S. Prolonged therapy with ACE-inhibitors induces a regression of left ventricular hypertrophy of dialysed uremic patients independently from hypotensive effects. Am J Kidney Dis. 30:1997;659-664.
62. London G.M., Pannier B., Guerin A.P., Marchais S.J., Safar M.E., Cuche J.L. Cardiac hypertrophy, aortic compliance, peripheral resistance and wave reflection in end-stage renal disease. Comparative effects on ACE-inhibition and calcium channel blockade. Circulation. 90:1994;2786-2796.
63. Dyadyk A.I., Bagriy A.E., Lebed I.A., Yarovaya N.F., Taradin G.G. Captopril and enalapril induce decrease of left ventricular muscle mass in patients with end-stage renal failure. Timio M., Wizemann V., Venanzi S. Cardionephrology. 1995;363-365 Assisi, Italy.
64. Demuth K., Blacher J., Guerin A.P. et al. Endotelin and cardiovascular remodelling in end-stage renal disease. Nephrol Dial Transplant. 13:1998;375-383.
65. Aakhus S., Dahl K., Widerøe T.E. Cardiovascular morbidity and risk factors in renal transplant patients. Nephrol Dial Transplant. 14:1999;648-654.
66. Amann K., Ritz E. Reduced cardiac ischaemia tolerance in uraemia - what is the role of structural abnormalities of the heart? Nephrol Dial Transplant. 11:1996;1238-1241.
67. Wizemann V. Points to remember when dialysing the patient with coronary disease. Nephrol Dial Transplant. 11:1996;236-238.
68. Wizemann V., Kramer W. Cardiac arrhythmias in end-stage renal disease: prevalence, risk factors, and management. Parfrey P.S., Harnett J.D. Cardiac dysfunction in chronic uraemia. 1992;67-81 Kluwer Academic Publishers, Basel.
69. Redaelli B., Cavalli A., Catini R. et al. (Gruppo emodialisi e patologie cardiovasculari). Multicentre, cross-sectional study of ventricular arrhythmias in chronically haemodialysed patients. Lancet. 2:1988;305-308.
70. Wizemann V., Blank S., Kramer W. Diastolic dysfunction of the left ventricle in dialysis patients. Contrib Nephrol. 106:1994;106-109.
71. Wizemann V., Timio M., Alpert M.A., Kramer W. Options in dialysis therapy: significance of cardiovascular findings. Kidney Int. Suppl 40:1993;85-89.
72. Fujimoto S., Kagoshima T., Hashimoto T., Nakajima T., Dohi K. Left ventricular diastolic function in patients on maintenance hemodialysis: comparison with hypertensive heart disease and hypertrophic cardiomyopathy. Clin Nephrol. 42:1994;109-116.
73. Harnett J.D., Foley R.N., Kent G.M., Barre P.E., Murray D., Parfrey P.S. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int. 47:1995;884-890.
74. Harnett J.D., Kent G.M., Foley R.N., Parfrey P.S. Cardiac function and hematocrit level. Am J Kidney Dis. 25(Suppl 1):1995;S3-S7.
75. Himelman R.B., Lanzberg J.S., Simonson J.S. et al. Cardiac consequences of renal transplantation: changes in left ventricular morphology and function. J Am Coll Cardiol. 12:1988;915-923.
76. Peteiro J., Alvarez N., Calvio R. et al. Changes in left ventricular mass and filling after renal transplantation are related to changes in blood pressure: an echocardiographic and pulsed Doppler study. Cardiology. 85:1994;273-283.
77. Parfrey P.S., Harnett J.D., Foley R.N. et al. Impact of renal transplantation on uremic cardiomyopathy. Transplantation. 60:1995;908-914.
78. Cruickshank J.M., Lewis J., Moore V., Dodd C. Reversibility of left ventricular hypertrophy by different types of antihypertensive therapy. J Hum Hypertens. 6:1992;85-90.
79. Frohlich E.D. Current approaches in the treatment of hypertension. Curr Probl Cardiol. 19:1994;397-472.
80. Manzo M., Raiola P., Saggese A. et al. Effetti positivi dell'ACE inibitore nella cardiopatia dilatative in emodialisi periodica. Timio M., Wizemann V., Venanzi S. Cardionephrology. 1995;373-376 Assisi, Italy.
81. Tornig J., Amann K., Nichols C., Zeier M., Mall G., Ritz E. Differential effects of antihypertensive treatment on abnormal cardiac structure in experimental uremia. J Am Soc Nephrol. 5:1994;796.
82. Parfrey P.S., Harnett J.D. The management of cardiac disease in chronic uremia. Curr Opin Nephrol Hypertens. 3:1994;145-154.
83. Rambausek M., Mall G., Kollmar S., Ritz E. Effect of converting enzyme inhibitors on cardiac changes in experimental uremia. Kidney Int. 34(Suppl 25):1988;201-203.
84. Roithinger F.X., Punzengruber C., Wallner M. et al. The influence of ACE-inhibition on myocardial mass and diastolic function in chronic hemodialysis patients with adequate control of blood pressure. Clin Nephrol. 42:1994;309-314.
85. Dyadyk A.I., Bagriy A.E., Lebed I.A., Yarovaya N.F., Schukina E.V., Taradin G.G. ACE inhibitors captopril and enalapril induce regression of left ventricular hypertrophy in hypertensive patients with chronic renal failure. Nephrol Dial Transplant. 12:1997;945-951.
86. Eckardt K.-U. Cardiovascular consequences of renal anaemia and erythropoietin therapy. Nephrol Dial Transplant. 14:1999;1317-1323.
87. Zehnder C., Zuber M., Sulzer M. et al. Influence of long-term amelioration of anemia and blood pressure control on left ventricular hypertrophy in hemodialysed patients. Nephron. 61:1992;21-25.